SAN DIEGO, CA, June 26, 2025 /24-7PressRelease/ -- Dr. Ekaterina ("Katya") Suslova, has been selected for inclusion in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.

Dr. Ekaterina Suslova is a distinguished Research & Development (R&D) leader with over 15 years of experience spanning molecular diagnostics, preclinical development, and targeted therapeutic platforms. Her scientific leadership and cross-functional expertise have positioned her as a driver of innovation in translational biotechnology, precision-guided oncology, and integrated diagnostic systems. With a strong foundation in molecular biology and genetic engineering, she has evolved her focus toward strategic assay development, in vitro diagnostics (IVD), high-throughput screening (HTS), drug discovery, and stable biotech platform optimization for clinical and commercial deployment.

Her academic credentials include a PhD in molecular biology with distinction from Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry (IBCh), and a master's degree in biochemistry, summa cum laude, from Lomonosov Moscow State University (MSU).

Dr. Suslova gained international academic research experience as a visiting scientist at the University of Bristol, UK, La Trobe University in Melbourne, Australia, and Karolinska Institute in Stokholm, Sweden. She enhanced her industry perspective through a mini MBA in biopharma innovation from Rutgers Business School and completed advanced certifications from Thermo Fisher Scientific (Design Excellence Yellow Belt) and Harvard Medical School (HMX Immunology and Pharmacology).

Dr. Suslova is recognized for her ability to lead scientific teams, drive platform-level innovation, and guide translational strategies from discovery to commercialization. At Thermo Fisher Scientific in San Diego, she played a key scientific role in R&D initiatives supporting CRISPR-driven gene and cell therapy projects, contributing to the optimization of lentiviral and adenoviral platforms, cost-reduction strategies, technology transfer, and cross-functional collaboration with CRO partners. Her work focused on bridging early-stage research and pre-manufacturing solutions, helping advance scalable delivery technologies aligned with emerging therapeutic applications.

From 2020 to 2022, she served as a senior scientist and projects lead at Sakura Finetek USA in Los Angeles, where she advanced process and product development through manufacturing scale-up in the fields of automated tissue biopsy and immunohistopathology, downstream genomic analysis, clinical applications and life-saving oncology diagnostics. Prior to that, as a postdoctoral research fellow at Albert Einstein College of Medicine in New York (2017–2019), she developed biosensors, translational biomarkers, and intracellular signaling pathway modeling tools. From 2004 to 2017, she held progressive scientific leadership roles at IBCh, where she directed internationally funded research programs, built collaborative scientific teams, and pioneered innovations in fluorescent biosensor design and targeted oncology. Concurrently, she contributed to molecular tool commercialization at Evrogen JSC (2004–2015), and the development of product pipeline of advanced fluorescent technologies and assays that have been widely adopted by academic and industrial laboratories worldwide.

One of Dr. Suslova's signature achievements is the development and launch of several next-generation high-contrast fluorescent biosensors and biomarkers, created through advanced genetic engineering and directed protein evolution. These molecular tools have transformed real-time visualization of intracellular signaling and enzymatic activity, offering unprecedented precision and contrast. Her biosensors are now widely adopted across applications ranging from precision diagnostics and immuno-oncology to neuroscience and drug discovery.

Dr. Suslova's work has also contributed to advances in women's oncology, particularly through the development of high-specificity and high-sensitivity molecular assays used as companion diagnostics to guide targeted therapy selection and treatment monitoring. Her contributions to precision-guided oncology have advanced biomarker-enabled patient stratification, early detection, and the integration of diagnostics with emerging immunotherapies.

To remain at the forefront of innovations in life sciences, she maintains active affiliations with the Society for Neuroscience, the Physiological Society, Fluorescence Applications in Biotechnology and Life Sciences, and the Federation of European Biochemical Societies since 2007. In 2010 she contributed as a guest instructor at the White Sea Molecular Zoology School, mentoring students in hands-on molecular biology and fieldwork techniques.

Dr. Suslova is the author of 22 peer-reviewed publications, including articles in high-impact journals such as Nature Communications, Nature Methods, and Nature Biotechnology. She is internationally recognized for her expertise in translational strategy and development of molecular assays for diagnostics, targeted therapies, and biomarker-guided drug development. Her contributions have earned numerous honors, including the prestigious L'Oréal-UNESCO "Women in Science" Award and the European Academy Award for Young Scientists, reflecting her long-standing commitment to scientific excellence and global impact.

Outside of her scientific career, Dr. Suslova brings the same spirit of innovation, curiosity, and depth to her personal interests. A proud mother, she leads a vibrant and exploratory life beyond her professional responsibilities. She is a mountain enthusiast with a passion for alpine skiing, wilderness camping, swimming, attending live music events, and engaging in philosophical reading and personal growth. An avid cook, she enjoys discovering global cultures and cuisines through immersive travel.

Looking ahead, Dr. Suslova is actively pursuing executive leadership within the biopharmaceutical industry. She is committed to translating scientific innovation into real-world impact by advancing next-generation technologies in diagnostics, precision medicine, and therapeutic platforms. With a strong focus on scalability, access, and clinical decision-making, she aims to deliver solutions that improve patient outcomes at scale.

About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. The suite of Marquis® publications can be viewed at the official Marquis Who's Who® website, www.marquiswhoswho.com.

# # #